Carbenoxolone patients with gastric ulcers. A double-blind trial.
Carbenoxolone was compared with placebo in a randomised double-blind study involving 40 patients with gastric ulcer (20 each in the treated and placebo groups). The evaluation was based on eight variables. The endoscopic findings on completion of 4 or 6 weeks of treatment, revealed greater improvement in response to carbenoxolone than to placebo. The difference was statistically significant at the previously fixed level of significance of p less than 0.05. The plasma potassium level fell significantly in the treated group but the actual reduction of 7% was slight. No statistically significant differences were measured in any of the other variables, i.e. plasma sodium, SGOT, SGPT, systolic and diastolic blood pressure, bodyweight, or oedema formation.
D000328:Adult; D001835:Body Weight / Q000187:drug effects; D002229:Carbenoxolone / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004487:Edema / Q000139:chemically induced; D005260:Female; D005773:Gastroscopy; D006034:Glycyrrhetinic Acid / Q000031:analogs & derivatives*; D006801:Humans; D008297:Male; D011188:Potassium / Q000097:blood; D011897:Random Allocation; D013276:Stomach Ulcer / Q000188:drug therapy*
D002229:Carbenoxolone; D006034:Glycyrrhetinic Acid; D011188:Potassium